Patents by Inventor Robert A. Volkmann

Robert A. Volkmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS
    Publication number: 20260184820
    Abstract: The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.
    Type: Application
    Filed: July 25, 2025
    Publication date: July 2, 2026
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • HETEROARYL AMIDE INHIBITORS OF CD38
    Publication number: 20260167630
    Abstract: Disclosed are heteroaryl amide inhibitors of CD38 and methods of making and using the same in disease and disorder treatment.
    Type: Application
    Filed: November 21, 2025
    Publication date: June 18, 2026
    Inventors: ROBERT A. VOLKMANN, JOTHAM W. COE, ERIC VERDIN, ROSALBA PERRONE, MARGARET JACKSON, FREDERICK R. NELSON, ELENA SILVA, STEVE FELSTEAD
  • TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS
    Publication number: 20260042769
    Abstract: The present disclosure relates to compounds of the formula: and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain or hypertension.
    Type: Application
    Filed: October 21, 2025
    Publication date: February 12, 2026
    Inventors: Jotham W. COE, Robert L. DOW, John E. DONELLO, Bruce D. ROTH, Donald E. FRAIL, Daniel W. GIL, Robert A. VOLKMANN
  • Heteroaryl amide inhibitors of CD38
    Patent number: 12509451
    Abstract: Disclosed are heteroaryl amide inhibitors of CD38 and methods of making and using the same in disease and disorder treatment.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: December 30, 2025
    Assignees: NAPA THERAPEUTICS LIMITED, BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Robert A. Volkmann, Jotham W. Coe, Eric Verdin, Rosalba Perrone, Margaret Jackson, Frederick R. Nelson, Elena Silva, Steve Felstead
  • Methods for treatment of diseases involving acidic or hypoxic diseased tissues
    Patent number: 12427157
    Abstract: Compounds for treatment of diseases having acidic or hypoxic diseased tissues and pharmaceutical compositions comprising the compounds, as well as methods for making and using the compounds and compositions.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: September 30, 2025
    Assignee: Cybrexa 1, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Dalton King, Robert A. Volkmann, Yana Reshetnyak, Oleg Andreev, Donald Engleman
  • Peptide conjugates of cytotoxins as therapeutics
    Patent number: 12410262
    Abstract: The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: September 9, 2025
    Assignee: Cybrexa 2, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • NMDA receptor modulators and uses thereof
    Patent number: 12358929
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: September 14, 2023
    Date of Patent: July 15, 2025
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger, Yuelian Xu
  • Peptide conjugates of microtubule-targeting agents as therapeutics
    Patent number: 12234212
    Abstract: The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: February 25, 2025
    Assignee: Cybrexa 3, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20250034145
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: February 29, 2024
    Publication date: January 30, 2025
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B
    Patent number: 12161624
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: December 10, 2024
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 12162890
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: December 10, 2024
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B
    Patent number: 12145909
    Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: November 19, 2024
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20240294546
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Application
    Filed: September 14, 2023
    Publication date: September 5, 2024
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger, Yuelian Xu
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20240199617
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: July 13, 2023
    Publication date: June 20, 2024
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS
    Publication number: 20240067616
    Abstract: The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.
    Type: Application
    Filed: January 11, 2023
    Publication date: February 29, 2024
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS
    Publication number: 20240010755
    Abstract: The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.
    Type: Application
    Filed: February 27, 2023
    Publication date: January 11, 2024
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • Oxabicycloheptane prodrugs
    Patent number: 11866444
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: January 9, 2024
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert A. Volkmann, Anthony Marfat
  • HETEROARYL AMIDE INHIBITORS OF CD38
    Publication number: 20230382901
    Abstract: Disclosed are heteroaryl amide inhibitors of CD38 and methods of making and using the same in disease and disorder treatment.
    Type: Application
    Filed: October 8, 2021
    Publication date: November 30, 2023
    Inventors: Robert A. VOLKMANN, Jotham W. COE, Eric VERDIN, Rosalba PERRONE, Margaret JACKSON, Frederick R. NELSON, Elena SILVA, Steve FELSTEAD
  • Thienopyrimidinone NMDA receptor modulators and uses thereof
    Patent number: 11648253
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: May 16, 2023
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Peptide conjugates of cytotoxins as therapeutics
    Patent number: 11634508
    Abstract: The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: April 25, 2023
    Assignee: Cybrexa 2, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann